Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real World Study to Assess Overall Survival in Amyotrophic Lateral Sclerosis (ALS) Patients Treated with RADICAVA (Edaravone) Compared to a Control Group of Patients not Prescribed the Product

Next Previous
X
Search
Trial Profile

A Real World Study to Assess Overall Survival in Amyotrophic Lateral Sclerosis (ALS) Patients Treated with RADICAVA (Edaravone) Compared to a Control Group of Patients not Prescribed the Product

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma America

    • Most Recent Events

    • 20 May 2021 New trial record
    • 12 May 2021 According to a Mitsubishi Tanabe Pharma America media release, the company will be conducting further analysis of this real-world data with plans to submit the full results for publication in a peer-reviewed journal.
    • 12 May 2021 According to a Mitsubishi Tanabe Pharma America media release, analysis is still ongoing, and the company looks forward to sharing more details about the methodology and findings with the ALS scientific community.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top